Nutrition, metabolism, and cardiovascular diseases : NMCD · 2025
C-reactive protein-to-albumin ratio as a marker of frailty, impaired physical function, and mortality in older adults with heart failure.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matsuo Koji, Kamiya Kentaro, Maeda Daichi, Hamazaki Nobuaki, Uchida Shota, Yamashita Masashi, Konishi Masaaki, Kasai Takatoshi, Saito Hiroshi, Saito Kazuya, Kitai Takeshi, Iwata Kentaro, Jujo Kentaro, Wada Hiroshi, Maekawa Emi, Momomura Shin-Ichi, Kagiyama Nobuyuki, Matsue Yuya
Аннотация
BACKGROUND AND AIMS: Malnutrition and inflammation often coexist in older adults with heart failure (HF), but routine biomarkers that capture these interconnected processes are limited. We evaluated whether the C-reactive protein-to-albumin ratio (CAR), which indicates malnutrition and inflammation, is associated with frailty, physical performance, and mortality.
METHODS AND RESULTS: We conducted a post hoc analysis of consecutive hospitalised HF patients aged ≥ 65 years enrolled in the FRAGILE-HF study, a prospective, multi-centre observational study. CAR, calculated at discharge, was dichotomised at the third quartile (> 0.240). Physical frailty (Fried phenotype) and physical performance (Short Physical Performance Battery [SPPB], 6-min walk distance [6MWD], handgrip strength) were assessed at discharge. Logistic regression was used to evaluate associations with physical frailty and low physical performance. Cox proportional hazards models were used to assess all-cause mortality over 2 years. Of 1332 patients, 1272 (median age: 81 years; 57.7% male) were included in the analysis. After multivariable adjustment, high CAR was associated with Fried frailty (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.18-2.05; P = 0.002), SPPB ≤ 9 (OR, 1.86; 95% CI, 1.38-2.50; P < 0.001), 6MWD < 300 m (OR, 2.23; 95% CI, 1.61-3.09; P < 0.001), and weak handgrip strength (OR, 2.09; 95% CI, 1.49-2.92; P < 0.001). During follow-up, 266 deaths occurred. High CAR independently predicted mortality (hazard ratio [HR], 1.44; 95% CI, 1.11-1.87; P = 0.006).
CONCLUSION: CAR is an inexpensive and readily available marker that integrates inflammation and malnutrition, identifies physical frailty and impaired physical performance, and predicts mortality in older patients with HF.
CLINICAL TRIAL REGISTRATION: UMIN-CTR (UMIN000023929).
METHODS AND RESULTS: We conducted a post hoc analysis of consecutive hospitalised HF patients aged ≥ 65 years enrolled in the FRAGILE-HF study, a prospective, multi-centre observational study. CAR, calculated at discharge, was dichotomised at the third quartile (> 0.240). Physical frailty (Fried phenotype) and physical performance (Short Physical Performance Battery [SPPB], 6-min walk distance [6MWD], handgrip strength) were assessed at discharge. Logistic regression was used to evaluate associations with physical frailty and low physical performance. Cox proportional hazards models were used to assess all-cause mortality over 2 years. Of 1332 patients, 1272 (median age: 81 years; 57.7% male) were included in the analysis. After multivariable adjustment, high CAR was associated with Fried frailty (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.18-2.05; P = 0.002), SPPB ≤ 9 (OR, 1.86; 95% CI, 1.38-2.50; P < 0.001), 6MWD < 300 m (OR, 2.23; 95% CI, 1.61-3.09; P < 0.001), and weak handgrip strength (OR, 2.09; 95% CI, 1.49-2.92; P < 0.001). During follow-up, 266 deaths occurred. High CAR independently predicted mortality (hazard ratio [HR], 1.44; 95% CI, 1.11-1.87; P = 0.006).
CONCLUSION: CAR is an inexpensive and readily available marker that integrates inflammation and malnutrition, identifies physical frailty and impaired physical performance, and predicts mortality in older patients with HF.
CLINICAL TRIAL REGISTRATION: UMIN-CTR (UMIN000023929).
Предметные рубрики MeSH
HumansMaleFemaleAgedBiomarkersHeart FailureAged, 80 and overFrailtyProspective StudiesC-Reactive ProteinPredictive Value of TestsGeriatric AssessmentRisk FactorsFrail ElderlyPrognosisMalnutritionTime FactorsAge FactorsInflammationRisk AssessmentHand StrengthNutritional StatusSerum Albumin, HumanInflammation MediatorsFunctional Status